Pavitt Christopher, Waleed Mohammed, Arunothayaraj Sandeep, Michail Michael, Cockburn James, de Belder Adam, Hildick-Smith David
Sussex Cardiac Centre, Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Eastern Road, Brighton, BN2 5BE, England, United Kingdom.
J Invasive Cardiol. 2023 Jan;35(1):E37-E45. doi: 10.25270/jic/22.00261. Epub 2022 Dec 9.
Right bundle-branch block (RBBB) is a strong predictor of the development of high-grade AV block (AVB) after TAVI.
To assess mortality, length-of-hospital stay, and cost in patients with RBBB undergoing TAVI according to whether or not they had preprocedural permanent pacemaker (PPM) implantation.
A total of 121 patients with RBBB who underwent TAVI between 2009-2021 were included. A total of 41 patients (33.9%) received a prophylactic PPM by clinical preference and 45/80 patients (56%) received PPM after TAVI. Baseline characteristics were balanced. Mortality was similar at 5 years, with death in 17 patients (41.4%) in the prophylactic PPM group vs 27 (33.8%) in the no prophylactic PPM group (adjusted hazard ratio [HR], 1.27; 95% confidence interval [CI], 0.69-2.33; P=.44). Median survival for the prophylactic PPM (4.2 years), post TAVI PPM (4.5 years) and no pacemaker (4.7 years) groups was similar. Sixteen deaths (35.6%) occurred in those receiving PPM after TAVI and 11 deaths (31.4%) occurred in those not receiving PPM (HR, 0.95; 95% CI, 0.43-2.09; P=.90). Thirty-day all-cause mortality was similar. Compared with post-TAVI PPM, prophylactic PPM reduced hospital length of stay (4.3 ± 4.5 days vs 2.5 ± 1.6 days, respectively; P=.02). For the highest and lowest complication and comorbidity scores, prophylactic PPM resulted in cost savings of £297.32 (-2.9%) and excess cost of £423.89 (+5.6%), respectively. There were no major pacing-related complications.
More than half of patients with RBBB undergoing TAVI require PPM shortly after their valve implant. A prophylactic pacing strategy is safe, reduces length of hospital stay, and is cost effective in the United Kingdom.
右束支传导阻滞(RBBB)是经导管主动脉瓣置入术(TAVI)后发生高度房室传导阻滞(AVB)的有力预测指标。
根据术前是否植入永久性起搏器(PPM),评估接受TAVI的RBBB患者的死亡率、住院时间和费用。
纳入2009年至2021年间接受TAVI的121例RBBB患者。共有41例患者(33.9%)根据临床偏好接受了预防性PPM,45/80例患者(56%)在TAVI后接受了PPM。基线特征均衡。5年时死亡率相似,预防性PPM组17例患者(41.4%)死亡,非预防性PPM组27例患者(33.8%)死亡(调整后风险比[HR],1.27;95%置信区间[CI],0.69 - 2.33;P = 0.44)。预防性PPM组、TAVI后PPM组和未植入起搏器组的中位生存期相似。TAVI后接受PPM的患者中有16例死亡(35.6%),未接受PPM的患者中有11例死亡(31.4%)(HR,0.95;95% CI,0.43 - 2.09;P = 0.90)。30天全因死亡率相似。与TAVI后PPM相比,预防性PPM缩短了住院时间(分别为4.3±4.5天和2.5±1.6天;P = 0.02)。对于最高和最低并发症及合并症评分,预防性PPM分别节省了297.32英镑(-2.9%)的费用和产生了423.89英镑(+5.6%)的额外费用。没有与起搏相关的主要并发症。
超过一半接受TAVI的RBBB患者在瓣膜植入后不久需要PPM。预防性起搏策略是安全的,可缩短住院时间,且在英国具有成本效益。